ARA-290 (Cibinetide)
EPO-derived 11-mer · cytoprotective research peptide
Overview
ARA-290 (also known as Cibinetide or pHBSP) is an 11-amino-acid synthetic peptide derived from helix B of erythropoietin (EPO). The molecule was designed to retain the cytoprotective and anti-inflammatory effects of EPO signaling through the heteromeric Innate Repair Receptor (a complex of EPO-receptor and CD131) while completely losing the hematopoietic activity of EPO mediated by the classical EPO-receptor homodimer. The decoupling of tissue-protective from erythropoietic effects is the principal pharmacological achievement of ARA-290 and the basis for clinical development across diabetic neuropathy, sarcoidosis-associated small-fiber neuropathy, and corneal nerve damage research. Lyochem supplies ARA-290 acetate as a lyophilized powder at ≥99.0% HPLC purity. The 11-residue sequence is reliable in SPPS; the analytical packet covers peak-integration HPLC, mass spec, water content, and counter-ion. Sequence verification by LC-MS/MS is available on request. Standard fill sizes (10 mg and 16 mg) cover most research workflows; the 16 mg fill is referenced in some clinical protocols for direct lot-to-protocol mapping. Endotoxin (LAL) and microbial limits are recommended add-ons for any in vivo neuropathy or inflammation research because the readouts overlap with endotoxin-driven inflammation pathways.
Who buys this, and why
Buyers in this category are research labs studying immune-modulation, cytokine signalling, and antimicrobial activity. The defining QC requirement is bacterial-endotoxin control: many downstream assays (NF-κB reporters, macrophage-activation panels, neutrophil-priming readouts) are themselves activated by endotoxin contamination, so a clean LAL on the specific lot is a precondition rather than a nice-to-have. LL-37 and related cationic antimicrobial peptides additionally benefit from low-bind plasticware during dilution.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- 1208243-50-8
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 10 mg, 16 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Bacterial endotoxin (LAL, USP <85>) — recommended for in vivo work
- Microbial limits (USP <61>/<62>) on request
- Low-bind plasticware notes for cationic AMPs
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, not for in-vitro diagnostic use. For NF-κB reporter, macrophage, neutrophil, and any other endotoxin-sensitive assay, request LAL testing on the specific lot as a precondition.
Frequently asked questions
Why does ARA-290 lack the erythropoietic effects of EPO?▾
Native EPO signals through two distinct receptor complexes: the classical homodimeric EPO-receptor that drives erythropoiesis, and the heteromeric Innate Repair Receptor (EPO-receptor + CD131) that mediates tissue-protective and anti-inflammatory effects. ARA-290 was engineered as a small peptide derived from helix B of EPO that selectively binds the Innate Repair Receptor but not the homodimeric EPO-receptor. The biological consequence is that ARA-290 retains essentially all of the cytoprotective and anti-inflammatory effects of EPO without raising hematocrit, eliminating the dose-limiting cardiovascular risk that comes with erythropoietic activity in chronic-dosing contexts.
What's the typical research context for ARA-290?▾
ARA-290 has been studied in clinical and pre-clinical contexts including diabetic peripheral neuropathy, small-fiber neuropathy associated with sarcoidosis, corneal nerve damage and dry-eye disease, and inflammatory bowel disease models. The unifying theme is tissue protection in inflammatory and ischemic injury contexts, situations where EPO's cytoprotective signaling would be useful but its hematopoietic activity would be undesirable. The clinical-development program is owned by Araim Pharmaceuticals; published Phase 2 data exists for several indications.
Related peptides